<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article" xml:lang="en"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Arthritis Res Ther</journal-id><journal-id journal-id-type="iso-abbrev">Arthritis Res. Ther</journal-id><journal-title-group><journal-title>Arthritis Research &#x00026; Therapy</journal-title></journal-title-group><issn pub-type="ppub">1478-6354</issn><issn pub-type="epub">1478-6362</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">22494514</article-id><article-id pub-id-type="pmc">3446447</article-id><article-id pub-id-type="publisher-id">ar3796</article-id><article-id pub-id-type="doi">10.1186/ar3796</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Intimal lining layer macrophages but not synovial sublining macrophages display an IL-10 polarized-like phenotype in chronic synovitis</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="A1"><name><surname>Ambarus</surname><given-names>Carmen A</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I2">2</xref><email>c.a.ambarus@amc.nl</email></contrib><contrib contrib-type="author" id="A2"><name><surname>Noordenbos</surname><given-names>Troy</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I2">2</xref><email>t.noordenbos@amc.nl</email></contrib><contrib contrib-type="author" id="A3"><name><surname>de Hair</surname><given-names>Maria JH</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>m.j.dehair@amc.nl</email></contrib><contrib contrib-type="author" id="A4"><name><surname>Tak</surname><given-names>Paul P</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I3">3</xref><email>p.p.tak@amc.nl</email></contrib><contrib contrib-type="author" id="A5"><name><surname>Baeten</surname><given-names>Dominique LP</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I2">2</xref><email>d.l.baeten@amc.nl</email></contrib></contrib-group><aff id="I1"><label>1</label>Department of Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands</aff><aff id="I2"><label>2</label>Department of Experimental Immunology, University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands</aff><aff id="I3"><label>3</label>GlaxoSmithKline, Gunnels Wood Road, Stevenage Herts, SG1 2NY, UK</aff><pub-date pub-type="ppub"><year>2012</year></pub-date><pub-date pub-type="epub"><day>11</day><month>4</month><year>2012</year></pub-date><volume>14</volume><issue>2</issue><fpage>R74</fpage><lpage>R74</lpage><history><date date-type="received"><day>27</day><month>2</month><year>2012</year></date><date date-type="rev-recd"><day>23</day><month>3</month><year>2012</year></date><date date-type="accepted"><day>11</day><month>4</month><year>2012</year></date></history><permissions><copyright-statement>Copyright &#x000a9;2012 Carmen A Ambarus; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2012</copyright-year><copyright-holder>Carmen A Ambarus; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><license-p>This is an open access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0">http://creativecommons.org/licenses/by/2.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:href="http://arthritis-research.com/content/14/2/R74"/><abstract><sec><title>Introduction</title><p>Synovial tissue macrophages play a key role in chronic inflammatory arthritis, but the contribution of different macrophage subsets in this process remains largely unknown. The main <italic>in vitro </italic>polarized macrophage subsets are classically (M1) and alternatively (M2) activated macrophages, the latter comprising interleukin (IL)-4 and IL-10 polarized cells. Here, we aimed to evaluate the polarization status of synovial macrophages in spondyloarthritis (SpA) and rheumatoid arthritis (RA).</p></sec><sec><title>Methods</title><p>Expression of polarization markers on synovial macrophages, peripheral blood monocytes, and <italic>in vitro </italic>polarized monocyte-derived macrophages from SpA versus RA patients was assessed by immunohistochemistry and flow cytometry, respectively. The polarization status of the intimal lining layer and the synovial sublining macrophages was assessed by double immunofluorescence staining.</p></sec><sec><title>Results</title><p>The expression of the IL-10 polarization marker cluster of differentiation 163 (CD163) was increased in SpA compared with RA intimal lining layer, but no differences were found in other M1 and M2 markers between the diseases. Furthermore, no significant phenotypic differences in monocytes and <italic>in vitro </italic>polarized monocyte-derived macrophages were seen between SpA, RA, and healthy controls, indicating that the differential CD163 expression does not reflect a preferential M2 polarization in SpA. More detailed analysis of intimal lining layer macrophages revealed a strong co-expression of the IL-10 polarization markers CD163 and cluster of differentiation 32 (CD32) but not any of the other markers in both SpA and RA. In contrast, synovial sublining macrophages had a more heterogeneous phenotype, with a majority of cells co-expressing M1 and M2 markers.</p></sec><sec><title>Conclusions</title><p>The intimal lining layer but not synovial sublining macrophages display an IL-10 polarized-like phenotype, with increased CD163 expression in SpA versus RA synovitis. These differences in the distribution of the polarized macrophage subset may contribute to the outcome of chronic synovitis.</p></sec></abstract></article-meta></front><body><sec><title>Introduction</title><p>The normal synovial membrane consists of two distinct structures: the intimal lining layer and the synovial sublining. The normal intimal lining layer comprises fibroblast-like synoviocytes and intimal lining layer macrophages, whereas the synovial sublining consists of connective tissue containing blood vessels, fibroblasts, adipocytes, and a limited number of resident immune cells, such as macrophages and mast cells [<xref ref-type="bibr" rid="B1">1</xref>]. Chronic inflammatory arthritis is histologically characterized by marked hyperplasia of the intimal lining layer and massive infiltration of the synovial sublining with innate and adaptive immune cells, which release inflammatory mediators, promote neoangiogenesis, and drive the destruction of adjacent cartilage and bone [<xref ref-type="bibr" rid="B2">2</xref>]. Macrophages play a major role in this process because they contribute to the intimal lining layer hyperplasia [<xref ref-type="bibr" rid="B3">3</xref>] and are the main producers of key inflammatory mediators, such as tumor necrosis factor (TNF) [<xref ref-type="bibr" rid="B4">4</xref>]. Accordingly, the number of synovial macrophages correlates with clinical disease activity [<xref ref-type="bibr" rid="B2">2</xref>,<xref ref-type="bibr" rid="B5">5</xref>] and decreases after clinically efficient but not placebo treatment in both rheumatoid arthritis (RA) [<xref ref-type="bibr" rid="B6">6</xref>-<xref ref-type="bibr" rid="B9">9</xref>] and spondyloarthritis (SpA) [<xref ref-type="bibr" rid="B10">10</xref>-<xref ref-type="bibr" rid="B13">13</xref>]. Furthermore, selective macrophage depletion has a strong antiinflammatory effect in animal models of arthritis [<xref ref-type="bibr" rid="B14">14</xref>].</p><p>Tissue macrophages consist of resident macrophages and monocytes that are recruited in inflammatory conditions and differentiate into macrophages on tissue entry. These macrophages represent a heterogeneous population, as local mediators can prime macrophages during their maturation and thereby shape their subsequent response to various activating stimuli [<xref ref-type="bibr" rid="B15">15</xref>,<xref ref-type="bibr" rid="B16">16</xref>]. Initially, two main polarized macrophage subsets were described based on their pro- versus antiinflammatory functions: classically activated macrophages (M1), which are specialized in the clearance of intracellular pathogens, and alternatively activated macrophages (M2), which have immunoregulatory properties and are involved in scavenging debris, angiogenesis, and tissue repair [<xref ref-type="bibr" rid="B17">17</xref>]. The M1 subset is induced mainly by interferon (IFN)-&#x003b3; (M&#x003a6;<sub>IFN-&#x003b3;</sub>), whereas M2 can be induced <italic>in vitro </italic>either by IL-4 (M&#x003a6;<sub>IL-4</sub>)/IL-13 or by IL-10 (M&#x003a6;<sub>IL-10</sub>) [<xref ref-type="bibr" rid="B17">17</xref>-<xref ref-type="bibr" rid="B20">20</xref>]. Whereas the macrophage polarization has been best described in rodents, we recently validated specific phenotypic markers [<xref ref-type="bibr" rid="B21">21</xref>] and distinct functional characteristics (unpublished observations) for these three main <italic>in vitro </italic>polarized macrophage subsets in humans.</p><p>The increasing knowledge of the phenotypic and functional diversity of human macrophages indicates that not only the overall number of macrophages in the inflamed tissue, but also their specific polarization status may determine the disease outcome in terms of severity, chronicity, and tissue damage. Interestingly, we previously described that, despite similar numbers of macrophages in RA and SpA synovitis, a selective overrepresentation of CD163<sup>+ </sup>macrophages was present in SpA [<xref ref-type="bibr" rid="B3">3</xref>,<xref ref-type="bibr" rid="B22">22</xref>-<xref ref-type="bibr" rid="B25">25</xref>]. CD163, the scavenger receptor for hemoglobin/haptoglobin complexes, is a known marker for IL-10 or M-CSF polarized M2 [<xref ref-type="bibr" rid="B21">21</xref>,<xref ref-type="bibr" rid="B26">26</xref>]. Together with the lower levels of M1-derived proinflammatory cytokines in SpA versus RA synovial fluid [<xref ref-type="bibr" rid="B27">27</xref>] and the defective IFN-&#x003b3; signature in SpA monocytes [<xref ref-type="bibr" rid="B28">28</xref>], these data suggest a preferential M2 polarization in SpA compared with an M1 polarization in RA. The aim of this study was to test this hypothesis by detailed characterization of distinct macrophage subsets in SpA and RA synovial tissue.</p></sec><sec sec-type="materials|methods"><title>Materials and methods</title><sec><title>Patients and samples</title><p>Peripheral blood samples were obtained from 11 SpA and eight RA patients and nine healthy controls. Synovial biopsies were obtained with small-bore arthroscopy from clinically inflamed knee joints, as previously described [<xref ref-type="bibr" rid="B29">29</xref>], and 18 SpA and 20 RA patients were included for the immunohistochemical analysis. All SpA patients fulfilled the criteria of the European Spondyloarthropathy Study Group (ESSG) [<xref ref-type="bibr" rid="B30">30</xref>], and all RA patients fulfilled the 1987 ACR classification criteria for RA [<xref ref-type="bibr" rid="B31">31</xref>]. Demographic and clinical data of the patients are shown in Table <xref ref-type="table" rid="T1">1</xref>. None of the patients was being treated with biologicals. All patients gave written informed consent to participate to the study, as approved by the Medical Ethics Committee of the Academic Medical Centre/University of Amsterdam.</p><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>Demographic and clinical features of the patients in the two cohorts</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th align="left" colspan="2">Cohort 1</th><th align="left" colspan="2">Cohort 2</th></tr><tr><th/><th colspan="4"><hr/></th></tr><tr><th/><th align="left">SpA<break/>(<italic>n </italic>= 18)</th><th align="left">RA<break/>(<italic>n </italic>= 20)</th><th align="left">SpA<break/>(<italic>n </italic>= 11)</th><th align="left">RA<break/>(<italic>n </italic>= 8)</th></tr></thead><tbody><tr><td align="left">Gender, % female</td><td align="left">40</td><td align="left">58</td><td align="left">33</td><td align="left">100</td></tr><tr><td colspan="5"><hr/></td></tr><tr><td align="left">Age, years</td><td align="left">47 (33-55)</td><td align="left">62 (53-74)</td><td align="left">38 (31-44)</td><td align="left">48 (32-63)</td></tr><tr><td colspan="5"><hr/></td></tr><tr><td align="left">Disease duration, years</td><td align="left">3 (1-29)</td><td align="left">3 (1-11)</td><td align="left">2 (1-4)</td><td align="left">2 (1-5)</td></tr><tr><td colspan="5"><hr/></td></tr><tr><td align="left">Swollen-joint count</td><td align="left">1 (1-2)</td><td align="left">8 (5-15)</td><td align="left">1 (0-1)</td><td align="left">1 (0-2)</td></tr><tr><td colspan="5"><hr/></td></tr><tr><td align="left">CRP, mg/L</td><td align="left">12 (5-31)</td><td align="left">19 (8-58)</td><td align="left">2 (1-7)</td><td align="left">5 (4-11)</td></tr><tr><td colspan="5"><hr/></td></tr><tr><td align="left">ESR, mm/hour</td><td align="left">29 (23-43)</td><td align="left">47 (33-66)</td><td align="left">2 (2-16)</td><td align="left">21 (13-29)</td></tr><tr><td colspan="5"><hr/></td></tr><tr><td align="left">% using DMARDs</td><td align="left">80</td><td align="left">54</td><td align="left">50</td><td align="left">100</td></tr></tbody></table><table-wrap-foot><p>As described in Materials and methods, synovial tissue biopsies were obtained from patients with spondyloarthritis (SpA) and rheumatoid arthritis (RA) (Cohort 1). Monocytes were isolated from peripheral blood of SpA and RA patients (Cohort 2). Except when indicated otherwise, values are expressed as the median (interquartile range). CRP, C-reactive protein; DMARD, disease-modifying anti-rheumatic drug; ESR, erythrocyte sedimentation rate.</p></table-wrap-foot></table-wrap></sec><sec><title>Immunohistochemistry</title><p>Synovial biopsy samples (six to eight per patient to minimize sampling error) were snap-frozen <italic>en bloc </italic>and mounted in Jung tissue-freezing medium (Leica Instruments, Nussloch, Germany). The acetone-fixed sections were stained by using mouse monoclonal antibodies directed toward CD68 (clone EBM-11; Dako, Heverlee, The Netherlands), CD64 (clone 10.1; BioLegend, Uithoorn, The Netherlands), CD14 (clone TUK4; Dako), CD163 (clone 5cFAT; BMA Biomedicals, Augst, Switzerland), and CD32 (clone AT10; abcam, Cambridge, UK). Sections were sequentially incubated with a biotinylated secondary antibody, a streptavidin-horseradish peroxidase link (LSAB; Dako), aminoethylcarbazole substrate as chromogen, and hematoxylin as counterstain [<xref ref-type="bibr" rid="B22">22</xref>,<xref ref-type="bibr" rid="B25">25</xref>]. Parallel sections were incubated with isotype- and concentration-matched monoclonal antibodies as negative controls. The expression of CD200R was assessed with immunofluorescence, by using a mouse monoclonal antibody (clone OX108; AbD Serotec, D&#x000fc;sseldorf, Germany). For each cohort, samples were stained in a single run, coded, and scored in a random order on a 4-point semiquantitative scale by two independent observers (CAA, TN), as described previously [<xref ref-type="bibr" rid="B5">5</xref>].</p></sec><sec><title>Monocyte isolation and <italic>in vitro </italic>polarization</title><p>Monocytes were isolated from peripheral blood with gradient centrifugation with Lymphoprep (Axis-Shield PoPAS, Oslo, Norway) and, subsequently, Percoll gradient separation (GE Healthcare, Uppsala, Sweden). Monocytes were analyzed immediately with flow cytometry or cultured at a concentration of 0.5 &#x000d7; 10<sup>6</sup>/ml in Iscove Modified Dulbecco Medium (IMDM) (Invitrogen, Breda, The Netherlands) supplemented with 10% fetal calf serum (FCS) (PAA Laboratories, C&#x000f6;lbe, Germany). Cultured monocytes were polarized <italic>in vitro </italic>with human recombinant IFN-&#x003b3; (10 ng/ml; R&#x00026;D Systems, Abingdon, UK), IL-4 (10 ng/ml; Miltenyi Biotec, Bergisch Gladbach, Germany), or IL-10 (10 ng/ml; R&#x00026;D Systems) for 4 days. For further analysis, polarized macrophages were recovered by scraping of the culture plate.</p></sec><sec><title>Flow cytometry</title><p>Surface-marker expression on monocytes and <italic>in vitro </italic>polarized macrophages was analyzed with flow cytometry (BD FACS Calibur Flow Cytometer, Erembodegem, Belgium) by using fluorochrome-labeled monoclonal antibodies against CD80 (clone L307.4; BD Pharmingen, Breda, the Netherlands), CD64 (clone 10.1; BioLegend), CD200R (clone OX108; AbD Serotec), CD14 (clone 61D3; eBioscience, San Diego, CA, USA), CD163 (clone GHI/61; BD Pharmingen), and CD16 (clone DJ130c; AbD Serotec, D&#x000fc;sseldorf, Germany). Equivalent amounts of isotype-matched control antibodies were included in all experiments as negative controls. Before staining, Fc receptors were blocked with 10% human serum (Lonza, Cologne, Germany). Data were analyzed with Flow Jo Flow Cytometry Analysis software (Tree Star, Ashland, OR, USA) after gating on the myeloid population in the FSC/SSC window. Values were expressed as the ratio of the geometric mean fluorescence intensity (gMFI) of the marker of interest over the gMFI of the isotype control.</p></sec><sec><title>Double immunofluorescence</title><p>Frozen synovial tissue sections were fixed in acetone and blocked with 10% goat serum (Dako, Glostrup, Denmark), followed by incubation with Biotin blocking system (Dako). Mouse monoclonal antibodies against CD80 (clone 2D10; BioLegend, Uithoorn, The Netherlands), CD64 (clone 10.1; BioLegend), CD200R (clone OX108; AbD Serotec, D&#x000fc;sseldorf, Germany), CD14 (clone TUK4; Dako), CD163 (clone 5cFAT; BMA Biomedicals, Augst, Switzerland), CD16 (clone HI16a; Abbiotec, San Diego, CA, USA), and CD32 (clone AT10; abcam, Cambridge, UK) were added, followed by incubation with Alexa-555-conjugated goat anti-mouse antibody (Molecular Probes Europe, Leiden, The Netherlands). After blocking with 10% mouse serum (Dako), the sections were incubated with biotinylated mouse monoclonal antibodies against CD68 (clone Y1/82A; BioLegend), CD64 (clone 10.1; BioLegend), CD200R (clone OX108; AbD Serotec), and CD163 (clone GHI/61; BioLegend). After incubation with streptavidin-Alexa 488 (Molecular Probes Europe, Leiden, The Netherlands), the slides were mounted with Vectashield containing DAPI (Vector Laboratories, Burlingame, CA, USA) and analyzed on a fluorescent imaging microscope (Leica DMRA, Wetzlar, Germany) coupled to a charge-coupled device (CCD) camera and Image-Pro Plus software (Media Cybernetics, Dutch Vision Components, Breda, The Netherlands). To quantify the coexpression of CD68 with CD64, CD200R, CD14, and CD163, the number of positively stained cells was counted in a minimum of five microscopic fields, and the percentage of double-positive cells from the total number of CD68-positive cells was calculated.</p></sec><sec><title>Statistics</title><p>Statistical analysis was performed by using Prism software (GraphPad, La Jolla, CA, USA). Data were expressed as median &#x000b1; interquartile range. A Mann-Whitney test was used for comparisons between two groups (SpA compared with RA) and ANOVA followed by a Bonferroni posttest was used for comparisons among more than two groups. A <italic>P </italic>value of less than 0.05 was considered statistically significant.</p></sec></sec><sec sec-type="results"><title>Results</title><sec><title>The expression of CD163 but not other M2 phenotypic markers is increased on intimal lining layer macrophages in SpA versus RA synovitis</title><p>To confirm and extend our previous description of increased CD163 expression in SpA compared with RA synovitis [<xref ref-type="bibr" rid="B3">3</xref>,<xref ref-type="bibr" rid="B22">22</xref>-<xref ref-type="bibr" rid="B25">25</xref>], we performed a detailed histologic analysis of the recently described panel of phenotypic markers for M&#x003a6;<sub>IFN-&#x003b3;</sub>, M&#x003a6;<sub>IL-4</sub>, and M&#x003a6;<sub>IL-10 </sub>[<xref ref-type="bibr" rid="B21">21</xref>]. As previously shown, the number of CD68<sup>+ </sup>macrophages in the intimal lining layer and synovial sublining was similar between the two diseases (Figure <xref ref-type="fig" rid="F1">1A, D</xref>), whereas CD163 expression was higher in the SpA compared with the RA intimal lining layer (<italic>P </italic>&#x0003c; 0.05) (Figure <xref ref-type="fig" rid="F1">1B</xref>), but similar in the synovial sublining (Figure <xref ref-type="fig" rid="F1">1E</xref>). However, the expression of another M&#x003a6;<sub>IL-10 </sub>marker, CD32, was similar in both diseases, for both the intimal lining layer and the synovial sublining (Figure <xref ref-type="fig" rid="F1">1C, F</xref>). The expression of the M&#x003a6;<sub>IFN-&#x003b3; </sub>marker CD64, the positive M&#x003a6;<sub>IL-4 </sub>marker CD200R, and the negative M&#x003a6;<sub>IL-4 </sub>marker CD14 was similar in the synovial sublining of SpA and RA (Figure <xref ref-type="fig" rid="F1">1G</xref> through <xref ref-type="fig" rid="F1">1I</xref>) and was very low to absent in the intimal lining layer (data not shown). These histologic data confirmed the higher CD163 expression in SpA compared with RA synovitis, but failed to provide additional evidence for a biased M2 polarization in SpA.</p><fig id="F1" position="float"><label>Figure 1</label><caption><p><bold>Immunohistochemical analysis of the expression of polarization markers in spondyloarthritis (SpA) compared with rheumatoid arthritis (RA) synovial tissue</bold>. The expression of CD68, CD163, and CD32 in the intimal lining layer <bold>(A through C) </bold>and the expression of CD68, CD64, CD200R, CD14, CD163 and CD32 in the synovial sublining <bold>(D through I) </bold>as assessed with semiquantitative scoring (0 to 3) of immunohistochemical stainings. Data are represented as median and interquartile range of 18 SpA and 20 RA patients.</p></caption><graphic xlink:href="ar3796-1"/></fig></sec><sec><title>The phenotype of peripheral blood monocytes is similar in SpA and RA</title><p>To investigate whether the increased expression of CD163 in SpA synovitis is related to preferential M&#x003a6;<sub>IL-10 </sub>polarization, we set up a series of additional experiments. Because monocytes from peripheral blood of SpA patients display a defective IFN-&#x003b3; signature [<xref ref-type="bibr" rid="B28">28</xref>] and IFN-&#x003b3; is the prototypic M1 polarizing cytokine, we first assessed whether not only intimal lining layer macrophages, but also peripheral blood monocytes have a distinct phenotype in SpA. We quantified the percentage of classic CD14<sup>+</sup>CD16<sup>- </sup>monocytes, intermediate CD14<sup>+</sup>CD16<sup>+ </sup>monocytes, and nonclassic CD14<sup>dim</sup>CD16<sup>+ </sup>monocytes [<xref ref-type="bibr" rid="B32">32</xref>] in peripheral blood from SpA and RA patients and healthy donors, and did not observe differences in these monocyte subsets between the groups (Figure <xref ref-type="fig" rid="F2">2A</xref>). We next assessed the expression of macrophage polarization markers on CD14<sup>+ </sup>monocytes and measured a marked expression of the M&#x003a6;<sub>IFN-&#x003b3; </sub>marker CD64 and a more modest expression of the M&#x003a6;<sub>IL-4 </sub>marker CD200R and the M&#x003a6;<sub>IL-10 </sub>marker CD16 (Figure <xref ref-type="fig" rid="F2">2B-D</xref>). However, no differences were found in the expression of these markers between SpA and RA patients and healthy controls. Expression of M&#x003a6;<sub>IFN-&#x003b3; </sub>marker CD80 and M&#x003a6;<sub>IL-10 </sub>marker CD163 on monocytes was very low (data not shown). Based on this assessment, no indication exists of phenotypic differences between monocytes from SpA and RA patients and healthy individuals.</p><fig id="F2" position="float"><label>Figure 2</label><caption><p><bold>Monocyte subsets and expression of phenotypic markers on spondyloarthritis (SpA) and rheumatoid arthritis (RA) patients and healthy donor monocytes</bold>. The percentage of CD14<sup>+</sup>CD16<sup>-</sup>, CD14<sup>+</sup>CD16<sup>+</sup>, and CD14<sup>dim</sup>CD16<sup>+ </sup>monocytes from SpA and RA patients and healthy donors was measured with flow cytometry <bold>(A)</bold>. Expression of CD64, CD200R, and CD16 on monocytes from SpA and RA patients and healthy donors was measured with flow cytometry and expressed as geometric mean fluorescence intensity (gMFI). Data are represented as median and interquartile range of at least seven independent experiments <bold>(B)</bold>.</p></caption><graphic xlink:href="ar3796-2"/></fig></sec><sec><title>The phenotype of <italic>in vitro </italic>polarized monocyte-derived macrophages is similar in SpA and RA</title><p>Further to investigate the propensity of monocytes to polarize preferentially toward a specific macrophage subset in SpA, monocytes from SpA and RA patients and healthy donors were polarized <italic>in vitro </italic>in the presence of IFN-&#x003b3;, IL-4, or IL-10. The expression of specific phenotypic markers was measured with flow cytometry after 4 days of polarization. On spontaneous macrophage maturation in the absence of polarizing cytokines, no differences were noted in the expression of phenotypic markers between SpA and RA patients and healthy donors (data not shown). As previously described in healthy donors [<xref ref-type="bibr" rid="B21">21</xref>], IFN-&#x003b3; specifically upregulated the membrane expression of CD80 and CD64, IL-4 upregulated CD200R and downregulated CD14, whereas IL-10 upregulated CD163 and CD16. After polarization of patient and healthy donor monocytes, we measured a similar modulation of these phenotypic markers in all three groups (Figure <xref ref-type="fig" rid="F3">3</xref>). In conclusion, we found no evidence for differences in the polarization potential of monocyte-derived macrophages from SpA and RA patients and healthy individuals.</p><fig id="F3" position="float"><label>Figure 3</label><caption><p><bold>Expression of phenotypic markers on <italic>in vitro </italic>polarized monocyte-derived macrophages from spondyloarthritis (SpA) and rheumatoid arthritis (RA) patients and healthy individuals</bold>. The expression of M&#x003a6;<sub>IFN-&#x003b3; </sub>markers CD80 and CD64, M&#x003a6;<sub>IL-4 </sub>markers CD200R and CD14, and M&#x003a6;<sub>IL-10 </sub>markers CD163 and CD16 was measured with flow cytometry on <italic>in vitro </italic>polarized monocyte-derived macrophages. Data are expressed as geometric mean fluorescence intensity (gMFI) of the marker expression after polarization with IFN-&#x003b3;, IL-4, or IL-10, respectively, divided by the gMFI of the marker expression on unpolarized macrophages. Data are represented as median and interquartile range of at least five independent experiments.</p></caption><graphic xlink:href="ar3796-3"/></fig></sec><sec><title>Intimal lining layer macrophages display a M&#x003a6;<sub>IL-10</sub>-like phenotype</title><p>Because we observed an increased expression of CD163, but no differences in the expression of other polarization markers in SpA compared with RA synovitis, we next performed double-immunofluorescence staining to characterize further the polarization phenotype of synovial macrophages. We studied the colocalization of pan-macrophage marker CD68 with M&#x003a6;<sub>IFN-&#x003b3; </sub>marker CD64 (Figure <xref ref-type="fig" rid="F4">4A</xref>), M&#x003a6;<sub>IL-4 </sub>markers CD200R and CD14 (Figure <xref ref-type="fig" rid="F4">4B, C</xref>), and M&#x003a6;<sub>IL-10 </sub>markers CD163, CD16, and CD32 (Figure <xref ref-type="fig" rid="F4">4D-F</xref>). Intimal lining layer CD68<sup>+ </sup>cells highly expressed the M&#x003a6;<sub>IL-10 </sub>markers CD163 and CD32 (Figure <xref ref-type="fig" rid="F4">4D, F</xref>), whereas the expression of CD64, CD80, CD200R, CD14, and CD16 was almost absent (Figure <xref ref-type="fig" rid="F4">4A-C</xref>, 4E) in both SpA and RA. In contrast, synovial sublining macrophages abundantly expressed both the M&#x003a6;<sub>IL-10 </sub>markers CD163 and CD32 (Figure <xref ref-type="fig" rid="F4">4D, F</xref>) and the M&#x003a6;<sub>IFN-&#x003b3; </sub>marker CD64 (Figure <xref ref-type="fig" rid="F4">4A</xref>). The positive M&#x003a6;<sub>IL-4 </sub>marker CD200R showed a low expression and low colocalization with CD68 (Figure <xref ref-type="fig" rid="F4">4B</xref>), whereas the negative M&#x003a6;<sub>IL-4 </sub>marker CD14 strongly colocalized with CD68 (Figure <xref ref-type="fig" rid="F4">4C</xref>). In agreement with previous reports, CD80 expression was almost absent in synovial tissue (data not shown) [<xref ref-type="bibr" rid="B33">33</xref>], whereas CD16 expression was low on CD68<sup>+ </sup>cells (Figure <xref ref-type="fig" rid="F4">4E</xref>). Although the number of samples used in these double-immunofluorescence experiments is too small for an accurate statistical analysis, quantification of the staining confirmed the lack of marked differences in the expression of these markers between SpA and RA synovial sublining macrophages (Figure <xref ref-type="fig" rid="F5">5</xref>). These findings suggest an M&#x003a6;<sub>IL-10</sub>-like phenotype of intimal lining layer macrophages in both SpA and RA, whereas synovial sublining macrophages had a more heterogeneous phenotype.</p><fig id="F4" position="float"><label>Figure 4</label><caption><p><bold>Double immunofluorescence stainings of CD68 and macrophage polarization markers on synovial tissue from chronic inflammatory arthritis</bold>. Colocalization of CD68 (green) with M&#x003a6;<sub>IFN-&#x003b3; </sub>marker CD64 <bold>(A)</bold>, M&#x003a6;<sub>IL-4 </sub>markers CD200R <bold>(B) </bold>and CD14 <bold>(C)</bold>, and M&#x003a6;<sub>IL-10 </sub>markers CD163 <bold>(D)</bold>, CD16 <bold>(E)</bold>, and CD32 <bold>(F) </bold>(red) on synovial tissue macrophages. Figures are representative of five spondyloarthritis (SpA) and five rheumatoid arthritis (RA) patients. Higher-magnification photos are included in each figure part.</p></caption><graphic xlink:href="ar3796-4"/></fig><fig id="F5" position="float"><label>Figure 5</label><caption><p><bold>Expression of polarization markers on CD68<sup>+ </sup>cells in synovial tissue from chronic inflammatory arthritis</bold>. Figure represents the percentage of CD64<sup>+ </sup><bold>(A)</bold>, CD200R<sup>+ </sup><bold>(B)</bold>, CD14<sup>+ </sup><bold>(C)</bold>, and CD163<sup>+ </sup><bold>(D) </bold>cells from the total number of CD68<sup>+ </sup>cells in five spondyloarthritis (SpA) and five rheumatoid arthritis (RA) patients. Data were acquired by manual quantitative scoring of double-immunofluorescence stainings and are represented as median and interquartile range.</p></caption><graphic xlink:href="ar3796-5"/></fig></sec><sec><title>Synovial sublining macrophages co-express M&#x003a6;<sub>INF-&#x003b3; </sub>and M&#x003a6;<sub>IL-10 </sub>markers</title><p>To characterize further the phenotype of synovial sublining macrophages, we studied the colocalization of M&#x003a6;<sub>IFN-&#x003b3; </sub>marker CD64 with CD200R, CD163, and CD32 (Figure <xref ref-type="fig" rid="F6">6A-C</xref>), colocalization of M&#x003a6;<sub>IL-4 </sub>marker CD200R with CD14, CD163, and CD32 (Figure <xref ref-type="fig" rid="F6">6D-F</xref>), and colocalization of M&#x003a6;<sub>IL-10 </sub>marker CD163 with CD14 and CD32 (Figure <xref ref-type="fig" rid="F6">6G, H</xref>). These stainings confirmed that both M&#x003a6;<sub>IL-10 </sub>markers CD163 and CD32 were expressed on the same cells in SpA and RA synovitis (Figure <xref ref-type="fig" rid="F6">6H</xref>). However, we also observed a high degree of coexpression between the M&#x003a6;<sub>INF-&#x003b3; </sub>marker CD64 and the M&#x003a6;<sub>IL-10 </sub>markers CD163 and CD32 (Figure <xref ref-type="fig" rid="F6">6B, C</xref>). Furthermore, the smaller macrophage subset that expressed the M&#x003a6;<sub>IL-4 </sub>marker CD200R also appeared to coexpress CD64, CD14, CD163, and CD32 (Figure <xref ref-type="fig" rid="F6">6D-F</xref>). Taken together, these data indicate that synovial sublining macrophages display a mixed M&#x003a6;<sub>INF-&#x003b3;</sub>/M&#x003a6;<sub>IL-10 </sub>phenotype. Within this population, a smaller macrophage subset also coexpresses the M&#x003a6;<sub>IL-4 </sub>marker CD200R.</p><fig id="F6" position="float"><label>Figure 6</label><caption><p><bold>Double-immunofluorescence stainings of M&#x003a6;<sub>IFN-&#x003b3;</sub>, M&#x003a6;<sub>IL-4</sub>, and M&#x003a6;<sub>IL-10 </sub>polarization markers on synovial tissue from chronic inflammatory arthritis</bold>. Colocalization of M&#x003a6;<sub>IFN-&#x003b3; </sub>marker CD64 with CD200R <bold>(A)</bold>, CD163 <bold>(B)</bold>, and CD32 <bold>(C)</bold>, colocalization of M&#x003a6;<sub>IL-4 </sub>marker CD200R with CD14 <bold>(D)</bold>, CD163 <bold>(E)</bold>, and CD32 <bold>(F)</bold>, and colocalization of M&#x003a6;<sub>IL-10 </sub>marker CD163 with CD14 <bold>(G) </bold>and CD32 <bold>(H)</bold>. Figure parts are representative of five spondyloarthritis (SpA) and five rheumatoid arthritis <bold>(</bold>RA) patients.</p></caption><graphic xlink:href="ar3796-6"/></fig></sec></sec><sec sec-type="discussion"><title>Discussion</title><p>Synovial tissue macrophages play a key role in chronic inflammatory arthritis, but the distribution and the function of different macrophage subsets in this process remain largely unknown. Based on the increased CD163 expression in SpA synovitis [<xref ref-type="bibr" rid="B3">3</xref>,<xref ref-type="bibr" rid="B22">22</xref>-<xref ref-type="bibr" rid="B25">25</xref>], we proposed the hypothesis of a preferential M2 polarization in SpA, as opposed to an M1 polarization in RA [<xref ref-type="bibr" rid="B27">27</xref>]. The present study aimed to assess this hypothesis experimentally by a detailed characterization of macrophages in inflammatory arthritis, by using a recently validated panel of phenotypic markers for <italic>in vitro </italic>polarized human macrophage subsets [<xref ref-type="bibr" rid="B21">21</xref>]. Comparison of macrophage phenotypic marker expression between SpA and RA synovitis confirmed the higher expression of CD163 in the SpA intimal lining layer. Although previous reports showed increased CD163 expression in both the intimal lining layer and synovial sublining, the differences appeared to be larger in the intimal lining layer [<xref ref-type="bibr" rid="B3">3</xref>,<xref ref-type="bibr" rid="B22">22</xref>].</p><p>As CD163 is a prototypical marker for M&#x003a6;<sub>IL-10</sub>, we performed three types of experiments to assess whether the increased CD163 expression reflected a preferential M2 polarization in SpA. First, the previously described inverse IFN-&#x003b3; signature in monocytes from SpA patients [<xref ref-type="bibr" rid="B28">28</xref>] suggested that even before entering the synovial compartment, myeloid cells may be skewed to polarize toward M2 rather than M1. Our analysis of peripheral blood monocytes, however, did not reveal phenotypic differences between SpA, RA, and healthy controls. In humans, three monocyte subsets have been identified: classic CD14<sup>+</sup>CD16<sup>-</sup>, intermediate CD14<sup>+</sup>CD16<sup>+</sup>, and nonclassic CD14<sup>dim</sup>CD16<sup>+ </sup>monocytes. Among these subsets, CD14<sup>+</sup>CD16<sup>+ </sup>monocytes were described to be recruited in tissues during inflammation and to produce high amounts of TNF [<xref ref-type="bibr" rid="B32">32</xref>,<xref ref-type="bibr" rid="B34">34</xref>-<xref ref-type="bibr" rid="B37">37</xref>]. Although other publications report contrasting findings of either an increased [<xref ref-type="bibr" rid="B38">38</xref>-<xref ref-type="bibr" rid="B40">40</xref>] or a decreased [<xref ref-type="bibr" rid="B41">41</xref>] percentage of CD14<sup>+</sup>CD16<sup>+ </sup>monocytes in inflammatory compared with healthy conditions, our experiments did not identify differences in these monocyte subsets between SpA and RA patients and healthy donors. Additionally, we did not observe differential expression of other phenotypic markers, such as CD64, CD16, and CD32, whereas the expression of CD80 and CD163 was very low on peripheral monocytes, as previously described [<xref ref-type="bibr" rid="B42">42</xref>,<xref ref-type="bibr" rid="B43">43</xref>].</p><p>Second, we assessed whether a potential bias toward M2 may appear during the differentiation of monocytes toward macrophages. <italic>In vitro </italic>polarization experiments with monocyte-derived macrophages failed, however, to indicate preferential polarization to a distinct subset in SpA compared with RA patients and healthy donors. These data suggest that the CD163<sup>+ </sup>macrophage phenotype in SpA synovitis is determined by the local inflammatory milieu rather than by intrinsic myeloid alterations. Previous publications showing CD163 upregulation during <italic>in vitro </italic>macrophage maturation in the presence of SpA synovial fluid [<xref ref-type="bibr" rid="B27">27</xref>] and a strong synovial CD163 downregulation on effective antiinflammatory treatment [<xref ref-type="bibr" rid="B12">12</xref>,<xref ref-type="bibr" rid="B13">13</xref>] support this observation.</p><p>Third, we assessed whether the local upregulation of CD163 on intimal lining layer macrophages in SpA was associated with differential expression of other phenotypic polarization markers between SpA and RA. This was not the case, as, for example, both the M&#x003a6;<sub>IL-10 </sub>marker CD32 and the prototypical M&#x003a6;<sub>IFN-&#x003b3; </sub>marker CD64 were similarly expressed in both diseases. These data question whether the altered expression of CD163, which is a reliable M2 marker <italic>in vitro</italic>, necessarily reflects a marked M2 versus M1 polarization <italic>in vivo</italic>. Supporting the notion that the phenotype of macrophage subsets <italic>in vivo </italic>is more complex than the conceptual <italic>in vitro </italic>framework of M1 and M2, detailed double-staining analysis showed that synovial sublining macrophages display a mixed phenotypic profile with a high colocalization of M&#x003a6;<sub>IFN-&#x003b3; </sub>and M&#x003a6;<sub>IL-10 </sub>markers. Similar observations of mixed polarization profiles were already described for human adipose tissue macrophages (ATMs), which show features of both alternative (CD206, CD163, IL-10, TGF-&#x003b2;) and classic (TNF, IL-6, IL-23, IL-8) activation [<xref ref-type="bibr" rid="B44">44</xref>,<xref ref-type="bibr" rid="B45">45</xref>]. An important question raised by this <italic>in vivo </italic>complexity is whether these cells exert both the pro- and antiinflammatory functions, which have been attributed to M1 and M2 macrophages, respectively, or whether they are steady-state cells waiting for additional signals to determine their ultimate phenotype and function. The latter hypothesis implies a large plasticity of tissue macrophages, as previously suggested in tumor environment [<xref ref-type="bibr" rid="B46">46</xref>], adipose tissue [<xref ref-type="bibr" rid="B47">47</xref>], and atherosclerosis [<xref ref-type="bibr" rid="B48">48</xref>]. Tumor-associated macrophages were described to have M2 properties, with low inflammatory chemokine receptors, poor antigen presentation, high IL-10, and low IL-12 production [<xref ref-type="bibr" rid="B49">49</xref>-<xref ref-type="bibr" rid="B53">53</xref>]. Interestingly, polarization toward an M1-like phenotype was shown to suppress tumor progression [<xref ref-type="bibr" rid="B54">54</xref>]. Adipose tissue macrophages were also reported to switch from an M2-like phenotype in normal adipose tissue to an M1-like phenotype in diet-induced obesity [<xref ref-type="bibr" rid="B55">55</xref>,<xref ref-type="bibr" rid="B56">56</xref>], but reports exist of a predominant M2 activation in insulin resistance and obesity [<xref ref-type="bibr" rid="B57">57</xref>]. The same holds true for the macrophages in the vascular wall, which were described to switch from an M2- to an M1-like phenotype and become so-called foam cells [<xref ref-type="bibr" rid="B58">58</xref>-<xref ref-type="bibr" rid="B60">60</xref>], whereas other authors describe an accumulation of M2-like cells in the atherosclerotic plaque [<xref ref-type="bibr" rid="B61">61</xref>]. Although the interpretation of these studies remains difficult in the absence of single markers that can unequivocally discriminate between macrophage subsets <italic>in vivo </italic>[<xref ref-type="bibr" rid="B15">15</xref>], the macrophage phenotype in the synovial sublining may reflect the same plasticity as in tumors, fat tissue, and atherosclerosis.</p><p>In contrast with the mixed phenotype of synovial sublining macrophages, the intimal lining layer macrophages clearly displayed an M&#x003a6;<sub>IL-10</sub>-like phenotype. We observed the same differences between the phenotype of intimal lining layer and synovial sublining macrophages, not only in SpA and RA but also in gout synovitis (data not shown), suggesting that this macrophage distribution pattern is a global feature of synovial inflammation. Together with the low expression of CD14 in the intimal lining layer, this observation may fit a model according to which the intimal lining layer contains mainly mature resident macrophages, whereas the synovial sublining is actively infiltrated with immature monocyte-derived macrophages. This model is in agreement with publications showing that the number of synovial sublining but not intimal lining layer macrophages is associated with disease activity in RA and correlates with response to therapy [<xref ref-type="bibr" rid="B7">7</xref>-<xref ref-type="bibr" rid="B9">9</xref>].</p><p>Concerning the differences between SpA and RA, this model would predict that the synovial sublining is similarly infiltrated by monocyte-derived macrophages with a mixed phenotype in both pathologies. However, the MRP8/14<sup>+ </sup>infiltrating macrophages were shown to accumulate highly in the intimal lining layer in RA [<xref ref-type="bibr" rid="B3">3</xref>] and secrete a variety of proinflammatory mediators [<xref ref-type="bibr" rid="B62">62</xref>]. In contrast, the SpA intimal lining layer appears to consist mainly of resident, M&#x003a6;<sub>IL-10</sub>-like macrophages, which is in accordance with the lower levels of M1-derived cytokines in SpA compared with RA synovial fluid [<xref ref-type="bibr" rid="B27">27</xref>] and with the less-destructive appearance of SpA synovitis.</p><p>Based on these findings, modulating the polarization and/or the migration of distinct macrophage subsets to the intimal lining layer would represent interesting therapeutic approaches for chronic synovitis.</p></sec><sec><title>Abbreviations</title><p>CD32: cluster of differentiation 32; CD163: cluster of differentiation 163; FCS: fetal calf serum; gMFI: geometric mean fluorescence intensity; IMDM: Iscove Modified Dulbecco Medium; RA: rheumatoid arthritis; SpA: spondyloarthritis.</p></sec><sec><title>Competing interests</title><p>The authors declare that they have no competing interests.</p></sec><sec><title>Authors' contributions</title><p>CAA, PPT, and DLPB participated in the design of the study. Acquisition of the data was performed by CAA, TN, and MJH. Data were analyzed and interpreted by CAA and TN. The manuscript was drafted by CAA and was revised by MJH, PPT, and DLPB. All authors read and approved the final manuscript.</p></sec></body><back><sec><title>Acknowledgements</title><p>DB is supported by a VIDI grant from The Netherlands Organization for Scientific Research (NWO) and by a grant from the Dutch Arthritis Foundation (Reumafonds).</p></sec><ref-list><ref id="B1"><mixed-citation publication-type="journal"><name><surname>Smith</surname><given-names>MD</given-names></name><name><surname>Barg</surname><given-names>E</given-names></name><name><surname>Weedon</surname><given-names>H</given-names></name><name><surname>Papengelis</surname><given-names>V</given-names></name><name><surname>Smeets</surname><given-names>T</given-names></name><name><surname>Tak</surname><given-names>PP</given-names></name><name><surname>Kraan</surname><given-names>M</given-names></name><name><surname>Coleman</surname><given-names>M</given-names></name><name><surname>Ahern</surname><given-names>MJ</given-names></name><article-title>Microarchitecture and protective mechanisms in synovial tissue from clinically and arthroscopically normal knee joints</article-title><source>Ann Rheum Dis</source><year>2003</year><volume>62</volume><fpage>303</fpage><lpage>307</lpage><pub-id pub-id-type="doi">10.1136/ard.62.4.303</pub-id><pub-id pub-id-type="pmid">12634226</pub-id></mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal"><name><surname>Tak</surname><given-names>PP</given-names></name><name><surname>Smeets</surname><given-names>TJ</given-names></name><name><surname>Daha</surname><given-names>MR</given-names></name><name><surname>Kluin</surname><given-names>PM</given-names></name><name><surname>Meijers</surname><given-names>KA</given-names></name><name><surname>Brand</surname><given-names>R</given-names></name><name><surname>Meinders</surname><given-names>AE</given-names></name><name><surname>Breedveld</surname><given-names>FC</given-names></name><article-title>Analysis of the synovial cell infiltrate in early rheumatoid synovial tissue in relation to local disease activity</article-title><source>Arthritis Rheum</source><year>1997</year><volume>40</volume><fpage>217</fpage><lpage>225</lpage><pub-id pub-id-type="doi">10.1002/art.1780400206</pub-id><pub-id pub-id-type="pmid">9041933</pub-id></mixed-citation></ref><ref id="B3"><mixed-citation publication-type="journal"><name><surname>De Rycke</surname><given-names>L</given-names></name><name><surname>Baeten</surname><given-names>D</given-names></name><name><surname>Foell</surname><given-names>D</given-names></name><name><surname>Kruithof</surname><given-names>E</given-names></name><name><surname>Veys</surname><given-names>EM</given-names></name><name><surname>Roth</surname><given-names>J</given-names></name><name><surname>De</surname><given-names>KF</given-names></name><article-title>Differential expression and response to anti-TNFalpha treatment of infiltrating versus resident tissue macrophage subsets in autoimmune arthritis</article-title><source>J Pathol</source><year>2005</year><volume>206</volume><fpage>17</fpage><lpage>27</lpage><pub-id pub-id-type="doi">10.1002/path.1758</pub-id><pub-id pub-id-type="pmid">15809977</pub-id></mixed-citation></ref><ref id="B4"><mixed-citation publication-type="journal"><name><surname>Tak</surname><given-names>PP</given-names></name><name><surname>Bresnihan</surname><given-names>B</given-names></name><article-title>The pathogenesis and prevention of joint damage in rheumatoid arthritis: advances from synovial biopsy and tissue analysis</article-title><source>Arthritis Rheum</source><year>2000</year><volume>43</volume><fpage>2619</fpage><lpage>2633</lpage><pub-id pub-id-type="doi">10.1002/1529-0131(200012)43:12&#x0003c;2619::AID-ANR1&#x0003e;3.0.CO;2-V</pub-id><pub-id pub-id-type="pmid">11145019</pub-id></mixed-citation></ref><ref id="B5"><mixed-citation publication-type="journal"><name><surname>Baeten</surname><given-names>D</given-names></name><name><surname>Kruithof</surname><given-names>E</given-names></name><name><surname>De</surname><given-names>RL</given-names></name><name><surname>Boots</surname><given-names>AM</given-names></name><name><surname>Mielants</surname><given-names>H</given-names></name><name><surname>Veys</surname><given-names>EM</given-names></name><name><surname>De</surname><given-names>KF</given-names></name><article-title>Infiltration of the synovial membrane with macrophage subsets and polymorphonuclear cells reflects global disease activity in spondyloarthropathy</article-title><source>Arthritis Res Ther</source><year>2005</year><volume>7</volume><fpage>R359</fpage><lpage>R369</lpage><pub-id pub-id-type="doi">10.1186/ar1501</pub-id><pub-id pub-id-type="pmid">15743484</pub-id></mixed-citation></ref><ref id="B6"><mixed-citation publication-type="journal"><name><surname>Baeten</surname><given-names>D</given-names></name><name><surname>Houbiers</surname><given-names>J</given-names></name><name><surname>Kruithof</surname><given-names>E</given-names></name><name><surname>Vandooren</surname><given-names>B</given-names></name><name><surname>Van den Bosch</surname><given-names>F</given-names></name><name><surname>Boots</surname><given-names>AM</given-names></name><name><surname>Veys</surname><given-names>EM</given-names></name><name><surname>Miltenburg</surname><given-names>AM</given-names></name><name><surname>De</surname><given-names>KF</given-names></name><article-title>Synovial inflammation does not change in the absence of effective treatment: implications for the use of synovial histopathology as biomarker in early phase clinical trials in rheumatoid arthritis</article-title><source>Ann Rheum Dis</source><year>2006</year><volume>65</volume><fpage>990</fpage><lpage>997</lpage><pub-id pub-id-type="doi">10.1136/ard.2005.047852</pub-id><pub-id pub-id-type="pmid">16414969</pub-id></mixed-citation></ref><ref id="B7"><mixed-citation publication-type="journal"><name><surname>Gerlag</surname><given-names>DM</given-names></name><name><surname>Haringman</surname><given-names>JJ</given-names></name><name><surname>Smeets</surname><given-names>TJ</given-names></name><name><surname>Zwinderman</surname><given-names>AH</given-names></name><name><surname>Kraan</surname><given-names>MC</given-names></name><name><surname>Laud</surname><given-names>PJ</given-names></name><name><surname>Morgan</surname><given-names>S</given-names></name><name><surname>Nash</surname><given-names>AF</given-names></name><name><surname>Tak</surname><given-names>PP</given-names></name><article-title>Effects of oral prednisolone on biomarkers in synovial tissue and clinical improvement in rheumatoid arthritis</article-title><source>Arthritis Rheum</source><year>2004</year><volume>50</volume><fpage>3783</fpage><lpage>3791</lpage><pub-id pub-id-type="doi">10.1002/art.20664</pub-id><pub-id pub-id-type="pmid">15593225</pub-id></mixed-citation></ref><ref id="B8"><mixed-citation publication-type="journal"><name><surname>Haringman</surname><given-names>JJ</given-names></name><name><surname>Gerlag</surname><given-names>DM</given-names></name><name><surname>Zwinderman</surname><given-names>AH</given-names></name><name><surname>Smeets</surname><given-names>TJ</given-names></name><name><surname>Kraan</surname><given-names>MC</given-names></name><name><surname>Baeten</surname><given-names>D</given-names></name><name><surname>McInnes</surname><given-names>IB</given-names></name><name><surname>Bresnihan</surname><given-names>B</given-names></name><name><surname>Tak</surname><given-names>PP</given-names></name><article-title>Synovial tissue macrophages: a sensitive biomarker for response to treatment in patients with rheumatoid arthritis</article-title><source>Ann Rheum Dis</source><year>2005</year><volume>64</volume><fpage>834</fpage><lpage>838</lpage><pub-id pub-id-type="doi">10.1136/ard.2004.029751</pub-id><pub-id pub-id-type="pmid">15576415</pub-id></mixed-citation></ref><ref id="B9"><mixed-citation publication-type="journal"><name><surname>Wijbrandts</surname><given-names>CA</given-names></name><name><surname>Vergunst</surname><given-names>CE</given-names></name><name><surname>Haringman</surname><given-names>JJ</given-names></name><name><surname>Gerlag</surname><given-names>DM</given-names></name><name><surname>Smeets</surname><given-names>TJ</given-names></name><name><surname>Tak</surname><given-names>PP</given-names></name><article-title>Absence of changes in the number of synovial sublining macrophages after ineffective treatment for rheumatoid arthritis: implications for use of synovial sublining macrophages as a biomarker</article-title><source>Arthritis Rheum</source><year>2007</year><volume>56</volume><fpage>3869</fpage><lpage>3871</lpage><pub-id pub-id-type="doi">10.1002/art.22964</pub-id><pub-id pub-id-type="pmid">17968928</pub-id></mixed-citation></ref><ref id="B10"><mixed-citation publication-type="journal"><name><surname>Baeten</surname><given-names>D</given-names></name><name><surname>Kruithof</surname><given-names>E</given-names></name><name><surname>Van den Bosch</surname><given-names>F</given-names></name><name><surname>Demetter</surname><given-names>P</given-names></name><name><surname>Van</surname><given-names>DN</given-names></name><name><surname>Cuvelier</surname><given-names>C</given-names></name><name><surname>De</surname><given-names>VM</given-names></name><name><surname>Mielants</surname><given-names>H</given-names></name><name><surname>Veys</surname><given-names>EM</given-names></name><name><surname>De</surname><given-names>KF</given-names></name><article-title>Immunomodulatory effects of anti-tumor necrosis factor alpha therapy on synovium in spondylarthropathy: histologic findings in eight patients from an open-label pilot study</article-title><source>Arthritis Rheum</source><year>2001</year><volume>44</volume><fpage>186</fpage><lpage>195</lpage><pub-id pub-id-type="doi">10.1002/1529-0131(200101)44:1&#x0003c;186::AID-ANR25&#x0003e;3.0.CO;2-B</pub-id><pub-id pub-id-type="pmid">11212159</pub-id></mixed-citation></ref><ref id="B11"><mixed-citation publication-type="journal"><name><surname>Canete</surname><given-names>JD</given-names></name><name><surname>Celis</surname><given-names>R</given-names></name><name><surname>Hernandez</surname><given-names>V</given-names></name><name><surname>Pablos</surname><given-names>JL</given-names></name><name><surname>Sanmarti</surname><given-names>R</given-names></name><article-title>Synovial immunopathological changes associated with successful abatacept therapy in a case of severe refractory psoriatic arthritis</article-title><source>Ann Rheum Dis</source><year>2010</year><volume>69</volume><fpage>935</fpage><lpage>936</lpage><pub-id pub-id-type="doi">10.1136/ard.2009.113233</pub-id><pub-id pub-id-type="pmid">19700394</pub-id></mixed-citation></ref><ref id="B12"><mixed-citation publication-type="journal"><name><surname>Kruithof</surname><given-names>E</given-names></name><name><surname>De</surname><given-names>RL</given-names></name><name><surname>Roth</surname><given-names>J</given-names></name><name><surname>Mielants</surname><given-names>H</given-names></name><name><surname>Van den Bosch</surname><given-names>F</given-names></name><name><surname>De</surname><given-names>KF</given-names></name><name><surname>Veys</surname><given-names>EM</given-names></name><name><surname>Baeten</surname><given-names>D</given-names></name><article-title>Immunomodulatory effects of etanercept on peripheral joint synovitis in the spondyloarthropathies</article-title><source>Arthritis Rheum</source><year>2005</year><volume>52</volume><fpage>3898</fpage><lpage>3909</lpage><pub-id pub-id-type="doi">10.1002/art.21426</pub-id><pub-id pub-id-type="pmid">16329106</pub-id></mixed-citation></ref><ref id="B13"><mixed-citation publication-type="journal"><name><surname>Kruithof</surname><given-names>E</given-names></name><name><surname>Baeten</surname><given-names>D</given-names></name><name><surname>Van den Bosch</surname><given-names>F</given-names></name><name><surname>Mielants</surname><given-names>H</given-names></name><name><surname>Veys</surname><given-names>EM</given-names></name><name><surname>De</surname><given-names>KF</given-names></name><article-title>Histological evidence that infliximab treatment leads to downregulation of inflammation and tissue remodelling of the synovial membrane in spondyloarthropathy</article-title><source>Ann Rheum Dis</source><year>2005</year><volume>64</volume><fpage>529</fpage><lpage>536</lpage><pub-id pub-id-type="doi">10.1136/ard.2003.018549</pub-id><pub-id pub-id-type="pmid">15388510</pub-id></mixed-citation></ref><ref id="B14"><mixed-citation publication-type="journal"><name><surname>van Lent</surname><given-names>PL</given-names></name><name><surname>Holthuysen</surname><given-names>AE</given-names></name><name><surname>Van</surname><given-names>RN</given-names></name><name><surname>Van De Putte</surname><given-names>LB</given-names></name><name><surname>van den Berg</surname><given-names>WB</given-names></name><article-title>Local removal of phagocytic synovial lining cells by clodronate-liposomes decreases cartilage destruction during collagen type II arthritis</article-title><source>Ann Rheum Dis</source><year>1998</year><volume>57</volume><fpage>408</fpage><lpage>413</lpage><pub-id pub-id-type="doi">10.1136/ard.57.7.408</pub-id><pub-id pub-id-type="pmid">9797567</pub-id></mixed-citation></ref><ref id="B15"><mixed-citation publication-type="journal"><name><surname>Murray</surname><given-names>PJ</given-names></name><name><surname>Wynn</surname><given-names>TA</given-names></name><article-title>Protective and pathogenic functions of macrophage subsets</article-title><source>Nat Rev Immunol</source><year>2011</year><volume>11</volume><fpage>723</fpage><lpage>737</lpage><pub-id pub-id-type="doi">10.1038/nri3073</pub-id><pub-id pub-id-type="pmid">21997792</pub-id></mixed-citation></ref><ref id="B16"><mixed-citation publication-type="journal"><name><surname>Hamilton</surname><given-names>JA</given-names></name><name><surname>Tak</surname><given-names>PP</given-names></name><article-title>The dynamics of macrophage lineage populations in inflammatory and autoimmune diseases</article-title><source>Arthritis Rheum</source><year>2009</year><volume>60</volume><fpage>1210</fpage><lpage>1221</lpage><pub-id pub-id-type="doi">10.1002/art.24505</pub-id><pub-id pub-id-type="pmid">19404968</pub-id></mixed-citation></ref><ref id="B17"><mixed-citation publication-type="journal"><name><surname>Stein</surname><given-names>M</given-names></name><name><surname>Keshav</surname><given-names>S</given-names></name><name><surname>Harris</surname><given-names>N</given-names></name><name><surname>Gordon</surname><given-names>S</given-names></name><article-title>Interleukin 4 potently enhances murine macrophage mannose receptor activity: a marker of alternative immunologic macrophage activation</article-title><source>J Exp Med</source><year>1992</year><volume>176</volume><fpage>287</fpage><lpage>292</lpage><pub-id pub-id-type="doi">10.1084/jem.176.1.287</pub-id><pub-id pub-id-type="pmid">1613462</pub-id></mixed-citation></ref><ref id="B18"><mixed-citation publication-type="journal"><name><surname>Gordon</surname><given-names>S</given-names></name><article-title>Alternative activation of macrophages</article-title><source>Nat Rev Immunol</source><year>2003</year><volume>3</volume><fpage>23</fpage><lpage>35</lpage><pub-id pub-id-type="doi">10.1038/nri978</pub-id><pub-id pub-id-type="pmid">12511873</pub-id></mixed-citation></ref><ref id="B19"><mixed-citation publication-type="journal"><name><surname>Mantovani</surname><given-names>A</given-names></name><name><surname>Sica</surname><given-names>A</given-names></name><name><surname>Sozzani</surname><given-names>S</given-names></name><name><surname>Allavena</surname><given-names>P</given-names></name><name><surname>Vecchi</surname><given-names>A</given-names></name><name><surname>Locati</surname><given-names>M</given-names></name><article-title>The chemokine system in diverse forms of macrophage activation and polarization</article-title><source>Trends Immunol</source><year>2004</year><volume>25</volume><fpage>677</fpage><lpage>686</lpage><pub-id pub-id-type="doi">10.1016/j.it.2004.09.015</pub-id><pub-id pub-id-type="pmid">15530839</pub-id></mixed-citation></ref><ref id="B20"><mixed-citation publication-type="journal"><name><surname>Mosser</surname><given-names>DM</given-names></name><name><surname>Edwards</surname><given-names>JP</given-names></name><article-title>Exploring the full spectrum of macrophage activation</article-title><source>Nat Rev Immunol</source><year>2008</year><volume>8</volume><fpage>958</fpage><lpage>969</lpage><pub-id pub-id-type="doi">10.1038/nri2448</pub-id><pub-id pub-id-type="pmid">19029990</pub-id></mixed-citation></ref><ref id="B21"><mixed-citation publication-type="journal"><name><surname>Ambarus</surname><given-names>CA</given-names></name><name><surname>Krausz</surname><given-names>S</given-names></name><name><surname>van</surname><given-names>EM</given-names></name><name><surname>Hamann</surname><given-names>J</given-names></name><name><surname>Radstake</surname><given-names>TR</given-names></name><name><surname>Reedquist</surname><given-names>KA</given-names></name><name><surname>Tak</surname><given-names>PP</given-names></name><name><surname>Baeten</surname><given-names>DL</given-names></name><article-title>Systematic validation of specific phenotypic markers for in vitro polarized human macrophages</article-title><source>J Immunol Methods</source><year>2012</year><volume>375</volume><fpage>196</fpage><lpage>206</lpage><pub-id pub-id-type="doi">10.1016/j.jim.2011.10.013</pub-id><pub-id pub-id-type="pmid">22075274</pub-id></mixed-citation></ref><ref id="B22"><mixed-citation publication-type="journal"><name><surname>Baeten</surname><given-names>D</given-names></name><name><surname>Demetter</surname><given-names>P</given-names></name><name><surname>Cuvelier</surname><given-names>CA</given-names></name><name><surname>Kruithof</surname><given-names>E</given-names></name><name><surname>Van</surname><given-names>DN</given-names></name><name><surname>De</surname><given-names>VM</given-names></name><name><surname>Veys</surname><given-names>EM</given-names></name><name><surname>De</surname><given-names>KF</given-names></name><article-title>Macrophages expressing the scavenger receptor CD163: a link between immune alterations of the gut and synovial inflammation in spondyloarthropathy</article-title><source>J Pathol</source><year>2002</year><volume>196</volume><fpage>343</fpage><lpage>350</lpage><pub-id pub-id-type="doi">10.1002/path.1044</pub-id><pub-id pub-id-type="pmid">11857499</pub-id></mixed-citation></ref><ref id="B23"><mixed-citation publication-type="journal"><name><surname>Baeten</surname><given-names>D</given-names></name><name><surname>Moller</surname><given-names>HJ</given-names></name><name><surname>Delanghe</surname><given-names>J</given-names></name><name><surname>Veys</surname><given-names>EM</given-names></name><name><surname>Moestrup</surname><given-names>SK</given-names></name><name><surname>De</surname><given-names>KF</given-names></name><article-title>Association of CD163<sup>+ </sup>macrophages and local production of soluble CD163 with decreased lymphocyte activation in spondylarthropathy synovitis</article-title><source>Arthritis Rheum</source><year>2004</year><volume>50</volume><fpage>1611</fpage><lpage>1623</lpage><pub-id pub-id-type="doi">10.1002/art.20174</pub-id><pub-id pub-id-type="pmid">15146432</pub-id></mixed-citation></ref><ref id="B24"><mixed-citation publication-type="journal"><name><surname>Kruithof</surname><given-names>E</given-names></name><name><surname>Baeten</surname><given-names>D</given-names></name><name><surname>De</surname><given-names>RL</given-names></name><name><surname>Vandooren</surname><given-names>B</given-names></name><name><surname>Foell</surname><given-names>D</given-names></name><name><surname>Roth</surname><given-names>J</given-names></name><name><surname>Canete</surname><given-names>JD</given-names></name><name><surname>Boots</surname><given-names>AM</given-names></name><name><surname>Veys</surname><given-names>EM</given-names></name><name><surname>De</surname><given-names>KF</given-names></name><article-title>Synovial histopathology of psoriatic arthritis, both oligo- and polyarticular, resembles spondyloarthropathy more than it does rheumatoid arthritis</article-title><source>Arthritis Res Ther</source><year>2005</year><volume>7</volume><fpage>R569</fpage><lpage>R580</lpage><pub-id pub-id-type="doi">10.1186/ar1698</pub-id><pub-id pub-id-type="pmid">15899044</pub-id></mixed-citation></ref><ref id="B25"><mixed-citation publication-type="journal"><name><surname>Noordenbos</surname><given-names>T</given-names></name><name><surname>Yeremenko</surname><given-names>N</given-names></name><name><surname>Gofita</surname><given-names>I</given-names></name><name><surname>van de Sande</surname><given-names>M</given-names></name><name><surname>Tak</surname><given-names>PP</given-names></name><name><surname>Canete</surname><given-names>JD</given-names></name><name><surname>Baeten</surname><given-names>D</given-names></name><article-title>Interleukin-17-positive mast cells contribute to synovial inflammation in spondylarthritis</article-title><source>Arthritis Rheum</source><year>2012</year><volume>64</volume><fpage>99</fpage><lpage>109</lpage><pub-id pub-id-type="doi">10.1002/art.33396</pub-id><pub-id pub-id-type="pmid">21968742</pub-id></mixed-citation></ref><ref id="B26"><mixed-citation publication-type="journal"><name><surname>Buechler</surname><given-names>C</given-names></name><name><surname>Ritter</surname><given-names>M</given-names></name><name><surname>Orso</surname><given-names>E</given-names></name><name><surname>Langmann</surname><given-names>T</given-names></name><name><surname>Klucken</surname><given-names>J</given-names></name><name><surname>Schmitz</surname><given-names>G</given-names></name><article-title>Regulation of scavenger receptor CD163 expression in human monocytes and macrophages by pro- and antiinflammatory stimuli</article-title><source>J Leukoc Biol</source><year>2000</year><volume>67</volume><fpage>97</fpage><lpage>103</lpage><pub-id pub-id-type="pmid">10648003</pub-id></mixed-citation></ref><ref id="B27"><mixed-citation publication-type="journal"><name><surname>Vandooren</surname><given-names>B</given-names></name><name><surname>Noordenbos</surname><given-names>T</given-names></name><name><surname>Ambarus</surname><given-names>C</given-names></name><name><surname>Krausz</surname><given-names>S</given-names></name><name><surname>Cantaert</surname><given-names>T</given-names></name><name><surname>Yeremenko</surname><given-names>N</given-names></name><name><surname>Boumans</surname><given-names>M</given-names></name><name><surname>Lutter</surname><given-names>R</given-names></name><name><surname>Tak</surname><given-names>PP</given-names></name><name><surname>Baeten</surname><given-names>D</given-names></name><article-title>Absence of a classically activated macrophage cytokine signature in peripheral spondylarthritis, including psoriatic arthritis</article-title><source>Arthritis Rheum</source><year>2009</year><volume>60</volume><fpage>966</fpage><lpage>975</lpage><pub-id pub-id-type="doi">10.1002/art.24406</pub-id><pub-id pub-id-type="pmid">19333931</pub-id></mixed-citation></ref><ref id="B28"><mixed-citation publication-type="journal"><name><surname>Smith</surname><given-names>JA</given-names></name><name><surname>Barnes</surname><given-names>MD</given-names></name><name><surname>Hong</surname><given-names>D</given-names></name><name><surname>DeLay</surname><given-names>ML</given-names></name><name><surname>Inman</surname><given-names>RD</given-names></name><name><surname>Colbert</surname><given-names>RA</given-names></name><article-title>Gene expression analysis of macrophages derived from ankylosing spondylitis patients reveals interferon-gamma dysregulation</article-title><source>Arthritis Rheum</source><year>2008</year><volume>58</volume><fpage>1640</fpage><lpage>1649</lpage><pub-id pub-id-type="doi">10.1002/art.23512</pub-id><pub-id pub-id-type="pmid">18512784</pub-id></mixed-citation></ref><ref id="B29"><mixed-citation publication-type="journal"><name><surname>van de Sande</surname><given-names>MG</given-names></name><name><surname>Gerlag</surname><given-names>DM</given-names></name><name><surname>Lodde</surname><given-names>BM</given-names></name><name><surname>van Baarsen</surname><given-names>LG</given-names></name><name><surname>Alivernini</surname><given-names>S</given-names></name><name><surname>Codullo</surname><given-names>V</given-names></name><name><surname>Felea</surname><given-names>I</given-names></name><name><surname>Vieira-Sousa</surname><given-names>E</given-names></name><name><surname>Fearon</surname><given-names>U</given-names></name><name><surname>Reece</surname><given-names>R</given-names></name><name><surname>Montecucco</surname><given-names>C</given-names></name><name><surname>Veale</surname><given-names>DJ</given-names></name><name><surname>Pitzalis</surname><given-names>C</given-names></name><name><surname>Emery</surname><given-names>P</given-names></name><name><surname>Klareskog</surname><given-names>L</given-names></name><name><surname>McInnes</surname><given-names>IB</given-names></name><name><surname>Tak</surname><given-names>PP</given-names></name><article-title>Evaluating antirheumatic treatments using synovial biopsy: a recommendation for standardisation to be used in clinical trials</article-title><source>Ann Rheum Dis</source><year>2011</year><volume>70</volume><fpage>423</fpage><lpage>427</lpage><pub-id pub-id-type="doi">10.1136/ard.2010.139550</pub-id><pub-id pub-id-type="pmid">21109518</pub-id></mixed-citation></ref><ref id="B30"><mixed-citation publication-type="journal"><name><surname>Dougados</surname><given-names>M</given-names></name><name><surname>van der Linden</surname><given-names>S</given-names></name><name><surname>Juhlin</surname><given-names>R</given-names></name><name><surname>Huitfeldt</surname><given-names>B</given-names></name><name><surname>Amor</surname><given-names>B</given-names></name><name><surname>Calin</surname><given-names>A</given-names></name><name><surname>Cats</surname><given-names>A</given-names></name><name><surname>Dijkmans</surname><given-names>B</given-names></name><name><surname>Olivieri</surname><given-names>I</given-names></name><name><surname>Pasero</surname><given-names>G</given-names></name><article-title>The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy</article-title><source>Arthritis Rheum</source><year>1991</year><volume>34</volume><fpage>1218</fpage><lpage>1227</lpage><pub-id pub-id-type="doi">10.1002/art.1780341003</pub-id><pub-id pub-id-type="pmid">1930310</pub-id></mixed-citation></ref><ref id="B31"><mixed-citation publication-type="journal"><name><surname>Arnett</surname><given-names>FC</given-names></name><name><surname>Edworthy</surname><given-names>SM</given-names></name><name><surname>Bloch</surname><given-names>DA</given-names></name><name><surname>McShane</surname><given-names>DJ</given-names></name><name><surname>Fries</surname><given-names>JF</given-names></name><name><surname>Cooper</surname><given-names>NS</given-names></name><name><surname>Healey</surname><given-names>LA</given-names></name><name><surname>Kaplan</surname><given-names>SR</given-names></name><name><surname>Liang</surname><given-names>MH</given-names></name><name><surname>Luthra</surname><given-names>HS</given-names></name><article-title>The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis</article-title><source>Arthritis Rheum</source><year>1988</year><volume>31</volume><fpage>315</fpage><lpage>324</lpage><pub-id pub-id-type="doi">10.1002/art.1780310302</pub-id><pub-id pub-id-type="pmid">3358796</pub-id></mixed-citation></ref><ref id="B32"><mixed-citation publication-type="journal"><name><surname>Cros</surname><given-names>J</given-names></name><name><surname>Cagnard</surname><given-names>N</given-names></name><name><surname>Woollard</surname><given-names>K</given-names></name><name><surname>Patey</surname><given-names>N</given-names></name><name><surname>Zhang</surname><given-names>SY</given-names></name><name><surname>Senechal</surname><given-names>B</given-names></name><name><surname>Puel</surname><given-names>A</given-names></name><name><surname>Biswas</surname><given-names>SK</given-names></name><name><surname>Moshous</surname><given-names>D</given-names></name><name><surname>Picard</surname><given-names>C</given-names></name><name><surname>Jais</surname><given-names>JP</given-names></name><name><surname>D'Cruz</surname><given-names>D</given-names></name><name><surname>Casanova</surname><given-names>JL</given-names></name><name><surname>Trouillet</surname><given-names>C</given-names></name><name><surname>Geissmann</surname><given-names>F</given-names></name><article-title>Human CD14dim monocytes patrol and sense nucleic acids and viruses via TLR7 and TLR8 receptors</article-title><source>Immunity</source><year>2010</year><volume>33</volume><fpage>375</fpage><lpage>386</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2010.08.012</pub-id><pub-id pub-id-type="pmid">20832340</pub-id></mixed-citation></ref><ref id="B33"><mixed-citation publication-type="journal"><name><surname>Balsa</surname><given-names>A</given-names></name><name><surname>Dixey</surname><given-names>J</given-names></name><name><surname>Sansom</surname><given-names>DM</given-names></name><name><surname>Maddison</surname><given-names>PJ</given-names></name><name><surname>Hall</surname><given-names>ND</given-names></name><article-title>Differential expression of the costimulatory molecules B7.1 (CD80) and B7.2 (CD86) in rheumatoid synovial tissue</article-title><source>Br J Rheumatol</source><year>1996</year><volume>35</volume><fpage>33</fpage><lpage>37</lpage><pub-id pub-id-type="doi">10.1093/rheumatology/35.1.33</pub-id><pub-id pub-id-type="pmid">8624620</pub-id></mixed-citation></ref><ref id="B34"><mixed-citation publication-type="journal"><name><surname>Belge</surname><given-names>KU</given-names></name><name><surname>Dayyani</surname><given-names>F</given-names></name><name><surname>Horelt</surname><given-names>A</given-names></name><name><surname>Siedlar</surname><given-names>M</given-names></name><name><surname>Frankenberger</surname><given-names>M</given-names></name><name><surname>Frankenberger</surname><given-names>B</given-names></name><name><surname>Espevik</surname><given-names>T</given-names></name><name><surname>Ziegler-Heitbrock</surname><given-names>L</given-names></name><article-title>The proinflammatory CD14+CD16+DR++ monocytes are a major source of TNF</article-title><source>J Immunol</source><year>2002</year><volume>168</volume><fpage>3536</fpage><lpage>3542</lpage><pub-id pub-id-type="pmid">11907116</pub-id></mixed-citation></ref><ref id="B35"><mixed-citation publication-type="journal"><name><surname>Geissmann</surname><given-names>F</given-names></name><name><surname>Auffray</surname><given-names>C</given-names></name><name><surname>Palframan</surname><given-names>R</given-names></name><name><surname>Wirrig</surname><given-names>C</given-names></name><name><surname>Ciocca</surname><given-names>A</given-names></name><name><surname>Campisi</surname><given-names>L</given-names></name><name><surname>Narni-Mancinelli</surname><given-names>E</given-names></name><name><surname>Lauvau</surname><given-names>G</given-names></name><article-title>Blood monocytes: distinct subsets, how they relate to dendritic cells, and their possible roles in the regulation of T-cell responses</article-title><source>Immunol Cell Biol</source><year>2008</year><volume>86</volume><fpage>398</fpage><lpage>408</lpage><pub-id pub-id-type="doi">10.1038/icb.2008.19</pub-id><pub-id pub-id-type="pmid">18392044</pub-id></mixed-citation></ref><ref id="B36"><mixed-citation publication-type="journal"><name><surname>Serbina</surname><given-names>NV</given-names></name><name><surname>Cherny</surname><given-names>M</given-names></name><name><surname>Shi</surname><given-names>C</given-names></name><name><surname>Bleau</surname><given-names>SA</given-names></name><name><surname>Collins</surname><given-names>NH</given-names></name><name><surname>Young</surname><given-names>JW</given-names></name><name><surname>Pamer</surname><given-names>EG</given-names></name><article-title>Distinct responses of human monocyte subsets to <italic>Aspergillus fumigatus </italic>conidia</article-title><source>J Immunol</source><year>2009</year><volume>183</volume><fpage>2678</fpage><lpage>2687</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.0803398</pub-id><pub-id pub-id-type="pmid">19635902</pub-id></mixed-citation></ref><ref id="B37"><mixed-citation publication-type="journal"><name><surname>Ziegler-Heitbrock</surname><given-names>L</given-names></name><article-title>The CD14<sup>+ </sup>CD16<sup>+ </sup>blood monocytes: their role in infection and inflammation</article-title><source>J Leukoc Biol</source><year>2007</year><volume>81</volume><fpage>584</fpage><lpage>592</lpage><pub-id pub-id-type="pmid">17135573</pub-id></mixed-citation></ref><ref id="B38"><mixed-citation publication-type="journal"><name><surname>Blom</surname><given-names>AB</given-names></name><name><surname>Radstake</surname><given-names>TR</given-names></name><name><surname>Holthuysen</surname><given-names>AE</given-names></name><name><surname>Sloetjes</surname><given-names>AW</given-names></name><name><surname>Pesman</surname><given-names>GJ</given-names></name><name><surname>Sweep</surname><given-names>FG</given-names></name><name><surname>van de Loo</surname><given-names>FA</given-names></name><name><surname>Joosten</surname><given-names>LA</given-names></name><name><surname>Barrera</surname><given-names>P</given-names></name><name><surname>van Lent</surname><given-names>PL</given-names></name><name><surname>van den Berg</surname><given-names>WB</given-names></name><article-title>Increased expression of Fcgamma receptors II and III on macrophages of rheumatoid arthritis patients results in higher production of tumor necrosis factor alpha and matrix metalloproteinase</article-title><source>Arthritis Rheum</source><year>2003</year><volume>48</volume><fpage>1002</fpage><lpage>1014</lpage><pub-id pub-id-type="doi">10.1002/art.10871</pub-id><pub-id pub-id-type="pmid">12687542</pub-id></mixed-citation></ref><ref id="B39"><mixed-citation publication-type="journal"><name><surname>Kawanaka</surname><given-names>N</given-names></name><name><surname>Yamamura</surname><given-names>M</given-names></name><name><surname>Aita</surname><given-names>T</given-names></name><name><surname>Morita</surname><given-names>Y</given-names></name><name><surname>Okamoto</surname><given-names>A</given-names></name><name><surname>Kawashima</surname><given-names>M</given-names></name><name><surname>Iwahashi</surname><given-names>M</given-names></name><name><surname>Ueno</surname><given-names>A</given-names></name><name><surname>Ohmoto</surname><given-names>Y</given-names></name><name><surname>Makino</surname><given-names>H</given-names></name><article-title>CD14<sup>+</sup>, CD16<sup>+ </sup>blood monocytes and joint inflammation in rheumatoid arthritis</article-title><source>Arthritis Rheum</source><year>2002</year><volume>46</volume><fpage>2578</fpage><lpage>2586</lpage><pub-id pub-id-type="doi">10.1002/art.10545</pub-id><pub-id pub-id-type="pmid">12384915</pub-id></mixed-citation></ref><ref id="B40"><mixed-citation publication-type="journal"><name><surname>Rossol</surname><given-names>M</given-names></name><name><surname>Kraus</surname><given-names>S</given-names></name><name><surname>Pierer</surname><given-names>M</given-names></name><name><surname>Baerwald</surname><given-names>C</given-names></name><name><surname>Wagner</surname><given-names>U</given-names></name><article-title>The CD14(bright) CD16<sup>+ </sup>monocyte subset is expanded in rheumatoid arthritis and promotes Th17 expansion</article-title><source>Arthritis Rheum</source><year>2012</year><volume>64</volume><issue>3</issue><fpage>671</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1002/art.33418</pub-id><pub-id pub-id-type="pmid">22006178</pub-id></mixed-citation></ref><ref id="B41"><mixed-citation publication-type="journal"><name><surname>Cairns</surname><given-names>AP</given-names></name><name><surname>Crockard</surname><given-names>AD</given-names></name><name><surname>Bell</surname><given-names>AL</given-names></name><article-title>The CD14<sup>+ </sup>CD16<sup>+ </sup>monocyte subset in rheumatoid arthritis and systemic lupus erythematosus</article-title><source>Rheumatol Int</source><year>2002</year><volume>21</volume><fpage>189</fpage><lpage>192</lpage><pub-id pub-id-type="pmid">11958435</pub-id></mixed-citation></ref><ref id="B42"><mixed-citation publication-type="journal"><name><surname>Fleischer</surname><given-names>J</given-names></name><name><surname>Soeth</surname><given-names>E</given-names></name><name><surname>Reiling</surname><given-names>N</given-names></name><name><surname>Grage-Griebenow</surname><given-names>E</given-names></name><name><surname>Flad</surname><given-names>HD</given-names></name><name><surname>Ernst</surname><given-names>M</given-names></name><article-title>Differential expression and function of CD80 (B7-1) and CD86 (B7-2) on human peripheral blood monocytes</article-title><source>Immunology</source><year>1996</year><volume>89</volume><fpage>592</fpage><lpage>598</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2567.1996.d01-785.x</pub-id><pub-id pub-id-type="pmid">9014827</pub-id></mixed-citation></ref><ref id="B43"><mixed-citation publication-type="journal"><name><surname>Sanchez</surname><given-names>C</given-names></name><name><surname>Domenech</surname><given-names>N</given-names></name><name><surname>Vazquez</surname><given-names>J</given-names></name><name><surname>Alonso</surname><given-names>F</given-names></name><name><surname>Ezquerra</surname><given-names>A</given-names></name><name><surname>Dominguez</surname><given-names>J</given-names></name><article-title>The porcine 2A10 antigen is homologous to human CD163 and related to macrophage differentiation</article-title><source>J Immunol</source><year>1999</year><volume>162</volume><fpage>5230</fpage><lpage>5237</lpage><pub-id pub-id-type="pmid">10227997</pub-id></mixed-citation></ref><ref id="B44"><mixed-citation publication-type="journal"><name><surname>Bourlier</surname><given-names>V</given-names></name><name><surname>Zakaroff-Girard</surname><given-names>A</given-names></name><name><surname>Miranville</surname><given-names>A</given-names></name><name><surname>De</surname><given-names>BS</given-names></name><name><surname>Maumus</surname><given-names>M</given-names></name><name><surname>Sengenes</surname><given-names>C</given-names></name><name><surname>Galitzky</surname><given-names>J</given-names></name><name><surname>Lafontan</surname><given-names>M</given-names></name><name><surname>Karpe</surname><given-names>F</given-names></name><name><surname>Frayn</surname><given-names>KN</given-names></name><name><surname>Bouloumie</surname><given-names>A</given-names></name><article-title>Remodeling phenotype of human subcutaneous adipose tissue macrophages</article-title><source>Circulation</source><year>2008</year><volume>117</volume><fpage>806</fpage><lpage>815</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.107.724096</pub-id><pub-id pub-id-type="pmid">18227385</pub-id></mixed-citation></ref><ref id="B45"><mixed-citation publication-type="journal"><name><surname>Zeyda</surname><given-names>M</given-names></name><name><surname>Farmer</surname><given-names>D</given-names></name><name><surname>Todoric</surname><given-names>J</given-names></name><name><surname>Aszmann</surname><given-names>O</given-names></name><name><surname>Speiser</surname><given-names>M</given-names></name><name><surname>Gyori</surname><given-names>G</given-names></name><name><surname>Zlabinger</surname><given-names>GJ</given-names></name><name><surname>Stulnig</surname><given-names>TM</given-names></name><article-title>Human adipose tissue macrophages are of an anti-inflammatory phenotype but capable of excessive pro-inflammatory mediator production</article-title><source>Int J Obesity (Lond)</source><year>2007</year><volume>31</volume><fpage>1420</fpage><lpage>1428</lpage><pub-id pub-id-type="doi">10.1038/sj.ijo.0803632</pub-id></mixed-citation></ref><ref id="B46"><mixed-citation publication-type="journal"><name><surname>Mantovani</surname><given-names>A</given-names></name><name><surname>Germano</surname><given-names>G</given-names></name><name><surname>Marchesi</surname><given-names>F</given-names></name><name><surname>Locatelli</surname><given-names>M</given-names></name><name><surname>Biswas</surname><given-names>SK</given-names></name><article-title>Cancer-promoting tumor-associated macrophages: new vistas and open questions</article-title><source>Eur J Immunol</source><year>2011</year><volume>41</volume><fpage>2522</fpage><lpage>2525</lpage><pub-id pub-id-type="doi">10.1002/eji.201141894</pub-id><pub-id pub-id-type="pmid">21952810</pub-id></mixed-citation></ref><ref id="B47"><mixed-citation publication-type="journal"><name><surname>Odegaard</surname><given-names>JI</given-names></name><name><surname>Chawla</surname><given-names>A</given-names></name><article-title>Alternative macrophage activation and metabolism</article-title><source>Annu Rev Pathol</source><year>2011</year><volume>6</volume><fpage>275</fpage><lpage>297</lpage><pub-id pub-id-type="doi">10.1146/annurev-pathol-011110-130138</pub-id><pub-id pub-id-type="pmid">21034223</pub-id></mixed-citation></ref><ref id="B48"><mixed-citation publication-type="journal"><name><surname>Wilson</surname><given-names>HM</given-names></name><article-title>Macrophages heterogeneity in atherosclerosis: implications for therapy</article-title><source>J Cell Mol Med</source><year>2010</year><volume>14</volume><fpage>2055</fpage><lpage>2065</lpage><pub-id pub-id-type="doi">10.1111/j.1582-4934.2010.01121.x</pub-id><pub-id pub-id-type="pmid">20629993</pub-id></mixed-citation></ref><ref id="B49"><mixed-citation publication-type="journal"><name><surname>Gocheva</surname><given-names>V</given-names></name><name><surname>Wang</surname><given-names>HW</given-names></name><name><surname>Gadea</surname><given-names>BB</given-names></name><name><surname>Shree</surname><given-names>T</given-names></name><name><surname>Hunter</surname><given-names>KE</given-names></name><name><surname>Garfall</surname><given-names>AL</given-names></name><name><surname>Berman</surname><given-names>T</given-names></name><name><surname>Joyce</surname><given-names>JA</given-names></name><article-title>IL-4 induces cathepsin protease activity in tumor-associated macrophages to promote cancer growth and invasion</article-title><source>Genes Dev</source><year>2010</year><volume>24</volume><fpage>241</fpage><lpage>255</lpage><pub-id pub-id-type="doi">10.1101/gad.1874010</pub-id><pub-id pub-id-type="pmid">20080943</pub-id></mixed-citation></ref><ref id="B50"><mixed-citation publication-type="journal"><name><surname>Imtiyaz</surname><given-names>HZ</given-names></name><name><surname>Williams</surname><given-names>EP</given-names></name><name><surname>Hickey</surname><given-names>MM</given-names></name><name><surname>Patel</surname><given-names>SA</given-names></name><name><surname>Durham</surname><given-names>AC</given-names></name><name><surname>Yuan</surname><given-names>LJ</given-names></name><name><surname>Hammond</surname><given-names>R</given-names></name><name><surname>Gimotty</surname><given-names>PA</given-names></name><name><surname>Keith</surname><given-names>B</given-names></name><name><surname>Simon</surname><given-names>MC</given-names></name><article-title>Hypoxia-inducible factor 2alpha regulates macrophage function in mouse models of acute and tumor inflammation</article-title><source>J Clin Invest</source><year>2010</year><volume>120</volume><fpage>2699</fpage><lpage>2714</lpage><pub-id pub-id-type="doi">10.1172/JCI39506</pub-id><pub-id pub-id-type="pmid">20644254</pub-id></mixed-citation></ref><ref id="B51"><mixed-citation publication-type="journal"><name><surname>Mantovani</surname><given-names>A</given-names></name><name><surname>Sozzani</surname><given-names>S</given-names></name><name><surname>Locati</surname><given-names>M</given-names></name><name><surname>Allavena</surname><given-names>P</given-names></name><name><surname>Sica</surname><given-names>A</given-names></name><article-title>Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes</article-title><source>Trends Immunol</source><year>2002</year><volume>23</volume><fpage>549</fpage><lpage>555</lpage><pub-id pub-id-type="doi">10.1016/S1471-4906(02)02302-5</pub-id><pub-id pub-id-type="pmid">12401408</pub-id></mixed-citation></ref><ref id="B52"><mixed-citation publication-type="journal"><name><surname>Sierra</surname><given-names>JR</given-names></name><name><surname>Corso</surname><given-names>S</given-names></name><name><surname>Caione</surname><given-names>L</given-names></name><name><surname>Cepero</surname><given-names>V</given-names></name><name><surname>Conrotto</surname><given-names>P</given-names></name><name><surname>Cignetti</surname><given-names>A</given-names></name><name><surname>Piacibello</surname><given-names>W</given-names></name><name><surname>Kumanogoh</surname><given-names>A</given-names></name><name><surname>Kikutani</surname><given-names>H</given-names></name><name><surname>Comoglio</surname><given-names>PM</given-names></name><name><surname>Tamagnone</surname><given-names>L</given-names></name><name><surname>Giordano</surname><given-names>S</given-names></name><article-title>Tumor angiogenesis and progression are enhanced by Sema4D produced by tumor-associated macrophages</article-title><source>J Exp Med</source><year>2008</year><volume>205</volume><fpage>1673</fpage><lpage>1685</lpage><pub-id pub-id-type="doi">10.1084/jem.20072602</pub-id><pub-id pub-id-type="pmid">18559453</pub-id></mixed-citation></ref><ref id="B53"><mixed-citation publication-type="journal"><name><surname>Steidl</surname><given-names>C</given-names></name><name><surname>Lee</surname><given-names>T</given-names></name><name><surname>Shah</surname><given-names>SP</given-names></name><name><surname>Farinha</surname><given-names>P</given-names></name><name><surname>Han</surname><given-names>G</given-names></name><name><surname>Nayar</surname><given-names>T</given-names></name><name><surname>Delaney</surname><given-names>A</given-names></name><name><surname>Jones</surname><given-names>SJ</given-names></name><name><surname>Iqbal</surname><given-names>J</given-names></name><name><surname>Weisenburger</surname><given-names>DD</given-names></name><name><surname>Bast</surname><given-names>MA</given-names></name><name><surname>Rosenwald</surname><given-names>A</given-names></name><name><surname>Muller-Hermelink</surname><given-names>HK</given-names></name><name><surname>Rimsza</surname><given-names>LM</given-names></name><name><surname>Campo</surname><given-names>E</given-names></name><name><surname>Delabie</surname><given-names>J</given-names></name><name><surname>Braziel</surname><given-names>RM</given-names></name><name><surname>Cook</surname><given-names>JR</given-names></name><name><surname>Tubbs</surname><given-names>RR</given-names></name><name><surname>Jaffe</surname><given-names>ES</given-names></name><name><surname>Lenz</surname><given-names>G</given-names></name><name><surname>Connors</surname><given-names>JM</given-names></name><name><surname>Staudt</surname><given-names>LM</given-names></name><name><surname>Chan</surname><given-names>WC</given-names></name><name><surname>Gascoyne</surname><given-names>RD</given-names></name><article-title>Tumor-associated macrophages and survival in classic Hodgkin's lymphoma</article-title><source>N Engl J Med</source><year>2010</year><volume>362</volume><fpage>875</fpage><lpage>885</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa0905680</pub-id><pub-id pub-id-type="pmid">20220182</pub-id></mixed-citation></ref><ref id="B54"><mixed-citation publication-type="journal"><name><surname>Duluc</surname><given-names>D</given-names></name><name><surname>Corvaisier</surname><given-names>M</given-names></name><name><surname>Blanchard</surname><given-names>S</given-names></name><name><surname>Catala</surname><given-names>L</given-names></name><name><surname>Descamps</surname><given-names>P</given-names></name><name><surname>Gamelin</surname><given-names>E</given-names></name><name><surname>Ponsoda</surname><given-names>S</given-names></name><name><surname>Delneste</surname><given-names>Y</given-names></name><name><surname>Hebbar</surname><given-names>M</given-names></name><name><surname>Jeannin</surname><given-names>P</given-names></name><article-title>Interferon-gamma reverses the immunosuppressive and protumoral properties and prevents the generation of human tumor-associated macrophages</article-title><source>Int J Cancer</source><year>2009</year><volume>125</volume><fpage>367</fpage><lpage>373</lpage><pub-id pub-id-type="doi">10.1002/ijc.24401</pub-id><pub-id pub-id-type="pmid">19378341</pub-id></mixed-citation></ref><ref id="B55"><mixed-citation publication-type="journal"><name><surname>Lumeng</surname><given-names>CN</given-names></name><name><surname>Bodzin</surname><given-names>JL</given-names></name><name><surname>Saltiel</surname><given-names>AR</given-names></name><article-title>Obesity induces a phenotypic switch in adipose tissue macrophage polarization</article-title><source>J Clin Invest</source><year>2007</year><volume>117</volume><fpage>175</fpage><lpage>184</lpage><pub-id pub-id-type="doi">10.1172/JCI29881</pub-id><pub-id pub-id-type="pmid">17200717</pub-id></mixed-citation></ref><ref id="B56"><mixed-citation publication-type="journal"><name><surname>Odegaard</surname><given-names>JI</given-names></name><name><surname>Ricardo-Gonzalez</surname><given-names>RR</given-names></name><name><surname>Goforth</surname><given-names>MH</given-names></name><name><surname>Morel</surname><given-names>CR</given-names></name><name><surname>Subramanian</surname><given-names>V</given-names></name><name><surname>Mukundan</surname><given-names>L</given-names></name><name><surname>Red</surname><given-names>EA</given-names></name><name><surname>Vats</surname><given-names>D</given-names></name><name><surname>Brombacher</surname><given-names>F</given-names></name><name><surname>Ferrante</surname><given-names>AW</given-names></name><name><surname>Chawla</surname><given-names>A</given-names></name><article-title>Macrophage-specific PPARgamma controls alternative activation and improves insulin resistance</article-title><source>Nature</source><year>2007</year><volume>447</volume><fpage>1116</fpage><lpage>1120</lpage><pub-id pub-id-type="doi">10.1038/nature05894</pub-id><pub-id pub-id-type="pmid">17515919</pub-id></mixed-citation></ref><ref id="B57"><mixed-citation publication-type="journal"><name><surname>Spencer</surname><given-names>M</given-names></name><name><surname>Yao-Borengasser</surname><given-names>A</given-names></name><name><surname>Unal</surname><given-names>R</given-names></name><name><surname>Rasouli</surname><given-names>N</given-names></name><name><surname>Gurley</surname><given-names>CM</given-names></name><name><surname>Zhu</surname><given-names>B</given-names></name><name><surname>Peterson</surname><given-names>CA</given-names></name><name><surname>Kern</surname><given-names>PA</given-names></name><article-title>Adipose tissue macrophages in insulin-resistant subjects are associated with collagen VI and fibrosis and demonstrate alternative activation</article-title><source>Am J Physiol Endocrinol Metab</source><year>2010</year><volume>299</volume><fpage>E1016</fpage><lpage>E1027</lpage><pub-id pub-id-type="doi">10.1152/ajpendo.00329.2010</pub-id><pub-id pub-id-type="pmid">20841504</pub-id></mixed-citation></ref><ref id="B58"><mixed-citation publication-type="journal"><name><surname>Li</surname><given-names>AC</given-names></name><name><surname>Glass</surname><given-names>CK</given-names></name><article-title>The macrophage foam cell as a target for therapeutic intervention</article-title><source>Nat Med</source><year>2002</year><volume>8</volume><fpage>1235</fpage><lpage>1242</lpage><pub-id pub-id-type="doi">10.1038/nm1102-1235</pub-id><pub-id pub-id-type="pmid">12411950</pub-id></mixed-citation></ref><ref id="B59"><mixed-citation publication-type="journal"><name><surname>Pinderski</surname><given-names>LJ</given-names></name><name><surname>Fischbein</surname><given-names>MP</given-names></name><name><surname>Subbanagounder</surname><given-names>G</given-names></name><name><surname>Fishbein</surname><given-names>MC</given-names></name><name><surname>Kubo</surname><given-names>N</given-names></name><name><surname>Cheroutre</surname><given-names>H</given-names></name><name><surname>Curtiss</surname><given-names>LK</given-names></name><name><surname>Berliner</surname><given-names>JA</given-names></name><name><surname>Boisvert</surname><given-names>WA</given-names></name><article-title>Overexpression of interleukin-10 by activated T lymphocytes inhibits atherosclerosis in LDL receptor-deficient mice by altering lymphocyte and macrophage phenotypes</article-title><source>Circ Res</source><year>2002</year><volume>90</volume><fpage>1064</fpage><lpage>1071</lpage><pub-id pub-id-type="doi">10.1161/01.RES.0000018941.10726.FA</pub-id><pub-id pub-id-type="pmid">12039795</pub-id></mixed-citation></ref><ref id="B60"><mixed-citation publication-type="journal"><name><surname>Khallou-Laschet</surname><given-names>J</given-names></name><name><surname>Varthaman</surname><given-names>A</given-names></name><name><surname>Fornasa</surname><given-names>G</given-names></name><name><surname>Compain</surname><given-names>C</given-names></name><name><surname>Gaston</surname><given-names>AT</given-names></name><name><surname>Clement</surname><given-names>M</given-names></name><name><surname>Dussiot</surname><given-names>M</given-names></name><name><surname>Levillain</surname><given-names>O</given-names></name><name><surname>Graff-Dubois</surname><given-names>S</given-names></name><name><surname>Nicoletti</surname><given-names>A</given-names></name><name><surname>Caligiuri</surname><given-names>G</given-names></name><article-title>Macrophage plasticity in experimental atherosclerosis</article-title><source>PLoS One</source><year>2010</year><volume>5</volume><fpage>e8852</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0008852</pub-id><pub-id pub-id-type="pmid">20111605</pub-id></mixed-citation></ref><ref id="B61"><mixed-citation publication-type="journal"><name><surname>Waldo</surname><given-names>SW</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Buono</surname><given-names>C</given-names></name><name><surname>Zhao</surname><given-names>B</given-names></name><name><surname>Billings</surname><given-names>EM</given-names></name><name><surname>Chang</surname><given-names>J</given-names></name><name><surname>Kruth</surname><given-names>HS</given-names></name><article-title>Heterogeneity of human macrophages in culture and in atherosclerotic plaques</article-title><source>Am J Pathol</source><year>2008</year><volume>172</volume><fpage>1112</fpage><lpage>1126</lpage><pub-id pub-id-type="doi">10.2353/ajpath.2008.070513</pub-id><pub-id pub-id-type="pmid">18321997</pub-id></mixed-citation></ref><ref id="B62"><mixed-citation publication-type="book"><name><surname>Bresnihan</surname><given-names>B</given-names></name><name><surname>Youssef</surname><given-names>P</given-names></name><person-group person-group-type="editor">Burke B, Lewis CE</person-group><article-title>Macrophages in rheumatoid arthritis</article-title><source>The Macrophage</source><year>2002</year><edition>2</edition><publisher-name>Oxford: Oxford University Press</publisher-name><fpage>231</fpage><lpage>433</lpage></mixed-citation></ref></ref-list></back></article>